Zobrazeno 1 - 10
of 299
pro vyhledávání: '"11"'
Autor:
Francis J. Hornicek, Zhenfeng Duan, Jacson Shen, Xianzhe Liu, Henry J. Mankin, Edwin Choy, Yan Gao, Wen Yang
Publikováno v:
Molecular Cancer Therapeutics. 15:1691-1701
Ovarian cancer is currently the most lethal gynecologic malignancy with limited treatment options. Improved targeted therapies are needed to combat ovarian cancer. Here, we report the identification of cyclin-dependent kinase 11 (CDK11) as a mediator
Autor:
Yves Pommier, Jane B. Trepel, Vinodh N. Rajapakse, Sai-Wen Tang, Susan E. Bates, Anish Thomas, Junko Murai
Purpose: Schlafen 11 (SLFN11), a putative DNA/RNA helicase is a dominant genomic determinant of response to DNA-damaging agents and is frequently not expressed in cancer cells. Whether histone deacetylase (HDAC) inhibitors can be used to release SLFN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::904d6a032a08c2a9acae31d241b8484d
https://europepmc.org/articles/PMC5899656/
https://europepmc.org/articles/PMC5899656/
Autor:
Marjo-Riitta Järvelin, Erikka Loftfield, Ville Karhunen, Yunhu Wan, J. Gregory Caporaso, Marc J. Gunter, Emily Vogtmann, Rob Knight, Rashmi Sinha, Minna Männikkö, Doratha A. Byrd, Karl-Heinz Herzig, Andriy Derkach
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 29, iss 11
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 29, iss 11
Background: Obesity is an established risk factor for multiple cancer types. Lower microbial richness has been linked to obesity, but human studies are inconsistent, and associations of early-life body mass index (BMI) with the fecal microbiome and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d339c5d13d9153c5c00c56d5a7df7c0b
https://europepmc.org/articles/PMC7642019/
https://europepmc.org/articles/PMC7642019/
Autor:
Vanessa Favasuli, Fortunato Morabito, Massimo Gentile, Katia Todoerti, Luca Baldini, Niccolo Bolli, Pellegrino Musto, Domenica Ronchetti, Umberto Gianelli, Elisa Taiana, Marta Lionetti, Noemi Puccio, Antonino Neri, I. Silvestris
Publikováno v:
Cancers, Vol 13, Iss 4898, p 4898 (2021)
Cancers
Cancers
Simple Summary The growing interest in BCL2 inhibitors for the treatment of multiple myeloma (MM) has led to the need for biomarkers that are able to predict patient’s sensitivity to the drug. The presence of the chromosomal translocation t(11;14)
Autor:
Shamit K. Dutta, Debabrata Mukhopadhyay, Hisato Kawakami, Shengbing Huang, Krishnendu Pal, Frank A. Sinicrope
Publikováno v:
Molecular Cancer Therapeutics. 15:3015-3027
Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated a
Publikováno v:
International Journal of Molecular Sciences; Volume 18; Issue 2; Pages: 395
International Journal of Molecular Sciences, Vol 18, Iss 2, p 395 (2017)
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 18, Iss 2, p 395 (2017)
International Journal of Molecular Sciences
Accumulative evidence demonstrates that the protein tyrosine phosphatase Shp2 functions as a powerful tumor promoter in many types of cancers. Abnormal expression of Shp2 has been implicated in many human malignancies. Overexpression of Shp2 in cance
Autor:
Elif Isik, Anthony Letai, Matthew S. Davids, Jennifer R. Brown, Jing Deng, Stacey M. Fernandes
Publikováno v:
Leukemia
Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial apoptosis in vitro, and as such the mechanisms underlying its ability to kill CLL cells are not we
Publikováno v:
Cancer Research. 72:5296-5306
Both activating and inactivating mutations in protein tyrosine phosphatase Ptpn11 (encoding Shp2) are associated with tumorigenesis. However, the underlying mechanisms remain unclear. Here, we show that Shp2 plays an important role in mitosis, dysreg
Autor:
Cristina Correia, Scott H. Kaufmann, Kevin L. Peterson, Paula A. Schneider, Brian D. Koh, Grzegorz S. Nowakowski, Husheng Ding
Publikováno v:
Leukemia
Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we
Autor:
Gary Lee Simmons, Paul Dent, Lora Kramer, Dustin Larsen, Justin D. Richey, Xin Yan Pei, Yun Dai, Mandy Garnett, Li Wang, Steven Grant, Daniella M. Schwartz, Jennifer Myers, Florence Su, Shuang Chen, Robert Z. Orlowski
Publikováno v:
Cancer Research. 72:4225-4237
BH3 mimetic drugs induce cell death by antagonizing the activity of antiapoptotic Bcl-2 family proteins. Cyclin-dependent kinase (CDK) inhibitors that function as transcriptional repressors downregulate the Bcl-2 family member Mcl-1 and increase the